Vor Biopharma (NASDAQ:VOR) Shares Down 6.2% – Should You Sell?

Posted by George Bondi on Jul 15th, 2026

Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report)’s share price traded down 6.2% on Monday . The company traded as low as $18.05 and last traded at $17.9550. Approximately 386,582 shares were traded during trading, a decline of 65% from the average daily volume of 1,104,882 shares. The stock had previously closed at $19.14.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price for the company. Wedbush raised their target price on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Read Our Latest Stock Analysis on Vor Biopharma

Vor Biopharma Price Performance

The business’s 50-day simple moving average is $15.85 and its two-hundred day simple moving average is $14.95.

Vor Biopharma (NASDAQ:VOR – Get Free Report) last posted its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Equities research analysts expect that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Buying and Selling at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director owned 2,402,095 shares in the company, valued at $37,881,038.15. The trade was a 6.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 795,524 shares of company stock worth $12,779,203. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vor Biopharma during the fourth quarter valued at about $36,000. Squarepoint Ops LLC acquired a new position in shares of Vor Biopharma in the third quarter valued at approximately $230,000. Bank of America Corp DE increased its stake in shares of Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after buying an additional 4,144 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after buying an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in Vor Biopharma in the 3rd quarter valued at approximately $304,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).